Kenta Yagi
Papers
1
Total Citations
17
H-Index
1
About
Kenta Yagi is a pharmacovigilance researcher whose work focuses on the intersection of drug safety and oncology, particularly concerning prostate cancer treatments. His most cited study, "Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects" (2021, 17 citations), addresses a critical safety gap in androgen deprivation therapy. By analyzing global adverse event databases, Yagi identified and characterized the risk of interstitial lung disease—a rare but serious complication—linked to antiandrogen drugs used in prostate cancer management. This work is especially significant given the dramatic rise in prostate cancer cases worldwide, from 679,023 in 2002 to over 1.27 million by 2018, highlighting the urgent need for safer pharmacological interventions. Yagi’s research provides clinicians with essential data to balance therapeutic efficacy against potential pulmonary risks, directly informing treatment decisions for patients undergoing hormone therapy. His contributions underscore a commitment to post-market drug surveillance and patient-centered outcomes, making him a valuable voice in the ongoing effort to improve the safety profile of cancer therapeutics.
Research Focus
Key Achievements
Top Papers
- 1